Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022

Nihad Elsadig Babiker; Bashir Ahmed Albashir Ahmed; Faihaa Alhady Alhussien Mohammed; Aamir Yassir Bashir Mohammed; Amna Ibrahim Hroon Abdelrhman; Duaa Adel Abdalrehim; Maye Mohammed Merghani; Tyseer Alabid

doi:doi:10.11648/j.ajcem.20231101.13

Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022

Nihad Elsadig Babiker, Bashir Ahmed Albashir Ahmed, Faihaa Alhady Alhussien Mohammed, Aamir Yassir Bashir Mohammed, Amna Ibrahim Hroon Abdelrhman, Duaa Adel Abdalrehim, Maye Mohammed Merghani, Tyseer Alabid

Published in American Journal of Clinical and Experimental Medicine (Volume 11, Issue 1)

Received: 15 November 2022 Accepted: 4 January 2023 Published: 13 January 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: A COVID 19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome corona virus 2. Ad26.COV2.S (Johnson & Johnson) vaccine is adenovirus vector-based vaccine that targets the spike protein of the SARS-CoV-2 virus, when it enters the body it stimulates the immune response. Materials and methods: This was a cross sectional study, health facility base, Conducted in Vaccine centre at Omer ben Alkhatab, Khartoum, Sudan during the period July to August, 2022 to estimate changes of coagulation parameters among Sudanese vaccinated with Johnson & Johnson vaccine. Sixty samples were collected from the Participants that took the first dose of Johnson & Johnson vaccine; thirty samples before the vaccination, and thirty after vaccination. The coagulation parameters were performing by different methods. Results: The means of parameters before the vaccination were; APTT was (36.2 ±3), PT was (15.8±2.4), INR (1.2 ±0.2), platelets (285.9 ±7.2), fibrinogen (243.4 ±4.6) and D-dimer (0.17±0.03). The means of parameters after the vaccination for the APTT, PT, INR, platelets count, fibrinogen and the D-dimer were; (35.2 ±2.9), (13.9±2.1), (1.21±0.3), (272.8±57.9), (284.2 ±53.3) and (0.37±0.8) respectively. When compared between the results of parameters per and post vaccination the results revealed that; there was significant decrease in the time for the APTT and PTT (p value ≤0.05), in significant differences with the INR and platelets count (p value ≥0.05), significant increase for the fibrinogen and D- dimer level (p value ≤0.05). While when compared the mean of the parameters with the age, genders, and symptoms there was insignificant differences (p value ≥0.05), except the D – dimer had a significant differences with the age and symptoms (p value ≤0.05). Conclusion: In the conclusion of this study there was significant decrease of the activated partial thromboplastin time (APTT), Prothrombin time (PT), and significant increase in fibrinogen and D-dimer level in the Sudanese individuals after the first dose of Johnson and Johnson Vaccine.

Published in	American Journal of Clinical and Experimental Medicine (Volume 11, Issue 1)
DOI	10.11648/j.ajcem.20231101.13
Page(s)	9-16
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

COVID 19, Vaccine Johnson and Johnson Vaccine, Coagulation, Fibrinogen, D-dimer

References

[1]	Yamada S, Asakura H. Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences 2022; 23 (6): 3338.
[2]	Sarkar M, Madabhavi IV, Quy PN, Govindagoudar MB. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review. Annals of Thoracic Medicine. 2022; 17 (1): 1.
[3]	Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. The American journal of emergency medicine. 2021; 49: 58-61.
[4]	Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Computational and structural biotechnology journal. 2021; 19: 2508-17.
[5]	Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. The Lancet Haematology. 2021; 11.
[6]	Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. Jama. 2021; 325 (15): 1575-.
[7]	Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. New England Journal of Medicine. 2021; 385 (18): 1680-9.
[8]	Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity ofthe ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminaryreport of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396 (10249): 467-478.
[9]	arawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-oldpost Covid-19 vaccine. Am J Hematol. 2021; 96 (5): E133-E134.12.
[10]	Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia followingPfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021; 96 (5): 534-537.
[11]	Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. Journal of the neurological sciences. 2021; 428: 117607.
[12]	Zazzeron L, Rosovsky RP, Bittner EA, Chang MG. Comparison of Published Guidelines for the Diagnosis and the Management of Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Explor. 2021; 3 (9): e0519. doi: 10.1097/CCE.0000000000000519. PMID: 34514421; PMCID: PMC8425820.
[13]	Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 2021; 121: 102663. doi: 10.1016/j.jaut.2021.102663. Epub 2021 May 18. PMID: 34020254; PMCID: PMC8129886.
[14]	Chen VM, Curnow JL, Tran HA, Choi PY. Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. Med J Aust. 2021 Sep 20; 215 (6): 245-249. e1. doi: 10.5694/mja2.51229. Epub 2021 Sep 6. Erratum in: Med J Aust. 2021 Nov 15; 215 (10): 453. PMID: 34490632; PMCID: PMC8661608.
[15]	See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021. Jama. 2021 Jun 22; 325 (24): 2448-56.
[16]	Gresele P, Momi S, Marcucci R, Ramundo F, De Stefano V, Tripodi A. Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica. 2021; 106 (12): 3034-3045. doi: 10.3324/haematol.2021.279289. PMID: 34407607; PMCID: PMC8634187.
[17]	Sue Pavord, F. R. C. Path., Marie Scully, Beverley J. Hunt, William Lester, Catherine Bagot, Brian Craven, M. B., B. Ch., Alex Rampotas, Gareth Ambler, Ph.D., and Mike Makris. Clinical Features ofVaccine-Induced Immune Thrombocytopenia and Thrombosis. nengl j med 2021; 385 (18): 1680-1689.
[18]	Waggiallah, Hisham Ali. “Thrombosis formation after COVID-19 vaccination Immunological Aspects: Review article.” Saudi journal of biological sciences vol. 29, 2 (2022): 1073-1078. doi: 10.1016/j.sjbs.2021.09.065
[19]	Sandhu, Bhuta, Carson, Konala, Biro, Manu, et al. [Internet]. American Journal of Therapeutics. [cited 2022Jun18]. Available from: http://www.americantherapeutics.com/
[20]	Warkentin TE, Cuker A. COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT). Update May. 2021; 7.
[21]	Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384: 2124.
[22]	Amged Hussein Abdelrhman, Ahmed Hosham, Duaa Sala, Marwan Adel, Nadeen wahbi, Sara Abdelrahim, Waad Abdullah, et al. The Effect of Covid-19 Astrazeneca Vaccines on Some Coagulation Profile (Pt, Aptt) Among Sudanese Two Dose Vaccinated. Journal of Medicine and Healthcare 2022; 494 1-3.
[23]	Abou-Ismail MY, Moser KA, Smock KJ, Lim MY. Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism. Am J Hematol. 2021 Sep 1; 96 (9): E346-E349. doi: 10.1002/ajh.26265. Epub 2021 Jun 17. PMID: 34096082; PMCID: PMC8212083.
[24]	Aimo C, Mariotti EB, Corrà A, et al. Stevens-Johnson syndrome induced by Vaxvetria (AZD1222) COVID-19 vaccine. Journal of the European Academy of Dermatology and Venereology: JEADV. 2022: 36 (6): e417-e419. DOI: 10.1111/jdv.17988. PMID: 35133674; PMCID: PMC9114927.
[25]	Gattringer T, Gressenberger P, Gary T, et al Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination Stroke and Vascular Neurology 2022; 7: doi: 10.1136/svn-2021-001142
[26]	Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26. COV2. S vaccination. New England Journal of Medicine. 2021 May 20; 384 (20): 1964-5.
[27]	Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW. Persistence of Ad26. COV2. S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. American journal of hematology. 2022 May; 97 (5): 519-26.
[28]	Haakonsen HB, Nystedt A. Deep vein thrombosis more than two weeks after vaccination against COVID-19. Tidsskr Nor Laegeforen. 2021 Apr 28; 141. English, Norwegian. doi: 10.4045/tidsskr.21.0274. PMID: 33928773.
[29]	Ben Saida I, Maatouk I, Toumi R, Bouslama E, Ben Ismail H, Ben Salem C, Boussarsar M. Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review. Vaccines (Basel). 2022 Jun 24; 10 (7): 1012. doi: 10.3390/vaccines10071012. PMID: 35891176; PMCID: PMC9319973.
[30]	Pai M. Epidemiology of VITT. Semin Hematol. 2022; 59 (2): 72-75. doi: 10.1053/j.seminhematol.2022.02.002. Epub 2022 Feb 8. PMID: 35512903; PMCID: PMC8820951.

Cite This Article

Plain Text BibTeX RIS

APA Style

Nihad Elsadig Babiker, Bashir Ahmed Albashir Ahmed, Faihaa Alhady Alhussien Mohammed, Aamir Yassir Bashir Mohammed, Amna Ibrahim Hroon Abdelrhman, et al. (2023). Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022. American Journal of Clinical and Experimental Medicine, 11(1), 9-16. https://doi.org/10.11648/j.ajcem.20231101.13

Copy | Download

ACS Style

Nihad Elsadig Babiker; Bashir Ahmed Albashir Ahmed; Faihaa Alhady Alhussien Mohammed; Aamir Yassir Bashir Mohammed; Amna Ibrahim Hroon Abdelrhman, et al. Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022. Am. J. Clin. Exp. Med. 2023, 11(1), 9-16. doi: 10.11648/j.ajcem.20231101.13

Copy | Download

AMA Style

Nihad Elsadig Babiker, Bashir Ahmed Albashir Ahmed, Faihaa Alhady Alhussien Mohammed, Aamir Yassir Bashir Mohammed, Amna Ibrahim Hroon Abdelrhman, et al. Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022. Am J Clin Exp Med. 2023;11(1):9-16. doi: 10.11648/j.ajcem.20231101.13

Copy | Download

@article{10.11648/j.ajcem.20231101.13,
  author = {Nihad Elsadig Babiker and Bashir Ahmed Albashir Ahmed and Faihaa Alhady Alhussien Mohammed and Aamir Yassir Bashir Mohammed and Amna Ibrahim Hroon Abdelrhman and Duaa Adel Abdalrehim and Maye Mohammed Merghani and Tyseer Alabid},
  title = {Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {11},
  number = {1},
  pages = {9-16},
  doi = {10.11648/j.ajcem.20231101.13},
  url = {https://doi.org/10.11648/j.ajcem.20231101.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20231101.13},
  abstract = {Background: A COVID 19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome corona virus 2. Ad26.COV2.S (Johnson & Johnson) vaccine is adenovirus vector-based vaccine that targets the spike protein of the SARS-CoV-2 virus, when it enters the body it stimulates the immune response. Materials and methods: This was a cross sectional study, health facility base, Conducted in Vaccine centre at Omer ben Alkhatab, Khartoum, Sudan during the period July to August, 2022 to estimate changes of coagulation parameters among Sudanese vaccinated with Johnson & Johnson vaccine. Sixty samples were collected from the Participants that took the first dose of Johnson & Johnson vaccine; thirty samples before the vaccination, and thirty after vaccination. The coagulation parameters were performing by different methods. Results: The means of parameters before the vaccination were; APTT was (36.2 ±3), PT was (15.8±2.4), INR (1.2 ±0.2), platelets (285.9 ±7.2), fibrinogen (243.4 ±4.6) and D-dimer (0.17±0.03). The means of parameters after the vaccination for the APTT, PT, INR, platelets count, fibrinogen and the D-dimer were; (35.2 ±2.9), (13.9±2.1), (1.21±0.3), (272.8±57.9), (284.2 ±53.3) and (0.37±0.8) respectively. When compared between the results of parameters per and post vaccination the results revealed that; there was significant decrease in the time for the APTT and PTT (p value ≤0.05), in significant differences with the INR and platelets count (p value ≥0.05), significant increase for the fibrinogen and D- dimer level (p value ≤0.05). While when compared the mean of the parameters with the age, genders, and symptoms there was insignificant differences (p value ≥0.05), except the D – dimer had a significant differences with the age and symptoms (p value ≤0.05). Conclusion: In the conclusion of this study there was significant decrease of the activated partial thromboplastin time (APTT), Prothrombin time (PT), and significant increase in fibrinogen and D-dimer level in the Sudanese individuals after the first dose of Johnson and Johnson Vaccine.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022
AU  - Nihad Elsadig Babiker
AU  - Bashir Ahmed Albashir Ahmed
AU  - Faihaa Alhady Alhussien Mohammed
AU  - Aamir Yassir Bashir Mohammed
AU  - Amna Ibrahim Hroon Abdelrhman
AU  - Duaa Adel Abdalrehim
AU  - Maye Mohammed Merghani
AU  - Tyseer Alabid
Y1  - 2023/01/13
PY  - 2023
N1  - https://doi.org/10.11648/j.ajcem.20231101.13
DO  - 10.11648/j.ajcem.20231101.13
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 9
EP  - 16
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20231101.13
AB  - Background: A COVID 19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome corona virus 2. Ad26.COV2.S (Johnson & Johnson) vaccine is adenovirus vector-based vaccine that targets the spike protein of the SARS-CoV-2 virus, when it enters the body it stimulates the immune response. Materials and methods: This was a cross sectional study, health facility base, Conducted in Vaccine centre at Omer ben Alkhatab, Khartoum, Sudan during the period July to August, 2022 to estimate changes of coagulation parameters among Sudanese vaccinated with Johnson & Johnson vaccine. Sixty samples were collected from the Participants that took the first dose of Johnson & Johnson vaccine; thirty samples before the vaccination, and thirty after vaccination. The coagulation parameters were performing by different methods. Results: The means of parameters before the vaccination were; APTT was (36.2 ±3), PT was (15.8±2.4), INR (1.2 ±0.2), platelets (285.9 ±7.2), fibrinogen (243.4 ±4.6) and D-dimer (0.17±0.03). The means of parameters after the vaccination for the APTT, PT, INR, platelets count, fibrinogen and the D-dimer were; (35.2 ±2.9), (13.9±2.1), (1.21±0.3), (272.8±57.9), (284.2 ±53.3) and (0.37±0.8) respectively. When compared between the results of parameters per and post vaccination the results revealed that; there was significant decrease in the time for the APTT and PTT (p value ≤0.05), in significant differences with the INR and platelets count (p value ≥0.05), significant increase for the fibrinogen and D- dimer level (p value ≤0.05). While when compared the mean of the parameters with the age, genders, and symptoms there was insignificant differences (p value ≥0.05), except the D – dimer had a significant differences with the age and symptoms (p value ≤0.05). Conclusion: In the conclusion of this study there was significant decrease of the activated partial thromboplastin time (APTT), Prothrombin time (PT), and significant increase in fibrinogen and D-dimer level in the Sudanese individuals after the first dose of Johnson and Johnson Vaccine.
VL  - 11
IS  - 1
ER  -

Copy | Download

Author Information

Nihad Elsadig Babiker

Faculty of Medical Laboratory Sciences, Darfur University College, Nyala, Sudan
Bashir Ahmed Albashir Ahmed

Faculty of Medical Laboratory Sciences, University of Medical Science and Technology, Khartoum, Sudan
Faihaa Alhady Alhussien Mohammed

Faculty of Medical Laboratory Sciences, University of Medical Science and Technology, Khartoum, Sudan
Aamir Yassir Bashir Mohammed

Faculty of Medical Laboratory Sciences, University of Medical Science and Technology, Khartoum, Sudan
Amna Ibrahim Hroon Abdelrhman

Faculty of Medical Laboratory Sciences, University of Medical Science and Technology, Khartoum, Sudan
Duaa Adel Abdalrehim

Faculty of Medical Laboratory Sciences, University of Medical Science and Technology, Khartoum, Sudan
Maye Mohammed Merghani

Faculty of Medical Laboratory Sciences, Nahda College, Khartoum, Sudan
Tyseer Alabid

Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Nihad Elsadig Babiker, Bashir Ahmed Albashir Ahmed, Faihaa Alhady Alhussien Mohammed, Aamir Yassir Bashir Mohammed, Amna Ibrahim Hroon Abdelrhman, et al. (2023). Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022. American Journal of Clinical and Experimental Medicine, 11(1), 9-16. https://doi.org/10.11648/j.ajcem.20231101.13

Copy | Download

ACS Style

Nihad Elsadig Babiker; Bashir Ahmed Albashir Ahmed; Faihaa Alhady Alhussien Mohammed; Aamir Yassir Bashir Mohammed; Amna Ibrahim Hroon Abdelrhman, et al. Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022. Am. J. Clin. Exp. Med. 2023, 11(1), 9-16. doi: 10.11648/j.ajcem.20231101.13

Copy | Download

AMA Style

Nihad Elsadig Babiker, Bashir Ahmed Albashir Ahmed, Faihaa Alhady Alhussien Mohammed, Aamir Yassir Bashir Mohammed, Amna Ibrahim Hroon Abdelrhman, et al. Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022. Am J Clin Exp Med. 2023;11(1):9-16. doi: 10.11648/j.ajcem.20231101.13

Copy | Download

@article{10.11648/j.ajcem.20231101.13,
  author = {Nihad Elsadig Babiker and Bashir Ahmed Albashir Ahmed and Faihaa Alhady Alhussien Mohammed and Aamir Yassir Bashir Mohammed and Amna Ibrahim Hroon Abdelrhman and Duaa Adel Abdalrehim and Maye Mohammed Merghani and Tyseer Alabid},
  title = {Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {11},
  number = {1},
  pages = {9-16},
  doi = {10.11648/j.ajcem.20231101.13},
  url = {https://doi.org/10.11648/j.ajcem.20231101.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20231101.13},
  abstract = {Background: A COVID 19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome corona virus 2. Ad26.COV2.S (Johnson & Johnson) vaccine is adenovirus vector-based vaccine that targets the spike protein of the SARS-CoV-2 virus, when it enters the body it stimulates the immune response. Materials and methods: This was a cross sectional study, health facility base, Conducted in Vaccine centre at Omer ben Alkhatab, Khartoum, Sudan during the period July to August, 2022 to estimate changes of coagulation parameters among Sudanese vaccinated with Johnson & Johnson vaccine. Sixty samples were collected from the Participants that took the first dose of Johnson & Johnson vaccine; thirty samples before the vaccination, and thirty after vaccination. The coagulation parameters were performing by different methods. Results: The means of parameters before the vaccination were; APTT was (36.2 ±3), PT was (15.8±2.4), INR (1.2 ±0.2), platelets (285.9 ±7.2), fibrinogen (243.4 ±4.6) and D-dimer (0.17±0.03). The means of parameters after the vaccination for the APTT, PT, INR, platelets count, fibrinogen and the D-dimer were; (35.2 ±2.9), (13.9±2.1), (1.21±0.3), (272.8±57.9), (284.2 ±53.3) and (0.37±0.8) respectively. When compared between the results of parameters per and post vaccination the results revealed that; there was significant decrease in the time for the APTT and PTT (p value ≤0.05), in significant differences with the INR and platelets count (p value ≥0.05), significant increase for the fibrinogen and D- dimer level (p value ≤0.05). While when compared the mean of the parameters with the age, genders, and symptoms there was insignificant differences (p value ≥0.05), except the D – dimer had a significant differences with the age and symptoms (p value ≤0.05). Conclusion: In the conclusion of this study there was significant decrease of the activated partial thromboplastin time (APTT), Prothrombin time (PT), and significant increase in fibrinogen and D-dimer level in the Sudanese individuals after the first dose of Johnson and Johnson Vaccine.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022
AU  - Nihad Elsadig Babiker
AU  - Bashir Ahmed Albashir Ahmed
AU  - Faihaa Alhady Alhussien Mohammed
AU  - Aamir Yassir Bashir Mohammed
AU  - Amna Ibrahim Hroon Abdelrhman
AU  - Duaa Adel Abdalrehim
AU  - Maye Mohammed Merghani
AU  - Tyseer Alabid
Y1  - 2023/01/13
PY  - 2023
N1  - https://doi.org/10.11648/j.ajcem.20231101.13
DO  - 10.11648/j.ajcem.20231101.13
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 9
EP  - 16
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20231101.13
AB  - Background: A COVID 19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome corona virus 2. Ad26.COV2.S (Johnson & Johnson) vaccine is adenovirus vector-based vaccine that targets the spike protein of the SARS-CoV-2 virus, when it enters the body it stimulates the immune response. Materials and methods: This was a cross sectional study, health facility base, Conducted in Vaccine centre at Omer ben Alkhatab, Khartoum, Sudan during the period July to August, 2022 to estimate changes of coagulation parameters among Sudanese vaccinated with Johnson & Johnson vaccine. Sixty samples were collected from the Participants that took the first dose of Johnson & Johnson vaccine; thirty samples before the vaccination, and thirty after vaccination. The coagulation parameters were performing by different methods. Results: The means of parameters before the vaccination were; APTT was (36.2 ±3), PT was (15.8±2.4), INR (1.2 ±0.2), platelets (285.9 ±7.2), fibrinogen (243.4 ±4.6) and D-dimer (0.17±0.03). The means of parameters after the vaccination for the APTT, PT, INR, platelets count, fibrinogen and the D-dimer were; (35.2 ±2.9), (13.9±2.1), (1.21±0.3), (272.8±57.9), (284.2 ±53.3) and (0.37±0.8) respectively. When compared between the results of parameters per and post vaccination the results revealed that; there was significant decrease in the time for the APTT and PTT (p value ≤0.05), in significant differences with the INR and platelets count (p value ≥0.05), significant increase for the fibrinogen and D- dimer level (p value ≤0.05). While when compared the mean of the parameters with the age, genders, and symptoms there was insignificant differences (p value ≥0.05), except the D – dimer had a significant differences with the age and symptoms (p value ≤0.05). Conclusion: In the conclusion of this study there was significant decrease of the activated partial thromboplastin time (APTT), Prothrombin time (PT), and significant increase in fibrinogen and D-dimer level in the Sudanese individuals after the first dose of Johnson and Johnson Vaccine.
VL  - 11
IS  - 1
ER  -

Copy | Download